Thrombolytic therapy remains a mainstay for the treatment of patients with acute myocardial
infarction. This therapy has been the subject of intense investigation and multiple studies as …

The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO) trial, a recent randomized “megatrial” of thrombolytic therapies …

Background The Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
(GUSTO-I) trial was designed to test whether thrombolytic strategies achieving more …

Background—Early reinfarction after thrombolytic therapy is associated with adverse
outcomes and increased mortality. Among patients with reinfarction in the 1992 Global …

Thrombolytic therapy for evolving acute myocardial infarction (AMI) reduces infarct size,
preserves ventricular function, and reduces mortality. Intravenous streptokinase is commonly …

OBJECTIVE: To review the literature on the use of thrombolytic agents in the
pharmacotherapeutic management of acute myocardial infarction (AMI). DATA SOURCE …

Thrombolytic therapy for the removal of intravascular thrombi was introduced when
streptokinase was first given to humans 40 years ago, the same year the American College …

Background—New recombinant plasminogen activators have been developed to simulate
the fibrinolytic action of the physiological serine protease tissue plasminogen activator …

Background In the randomized Global Utilization of t-PA and Streptokinase for Occluded
Coronary Arteries (GUSTO-I) trial, 41 021 patients received one of four thrombolytic …

Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been
developed, which differ in terms of effectiveness, complexity and costs. Reperfusion …